Mandarapharma

Mandara Pharma appears to be an active cannabinoid-focused pharmaceutical company with roots in Canada and operations spanning Colombia, Spain, and the United States. Its legacy business has centered on cannabis genetics, cultivation, extraction, formulation development, and commercialization infrastructure for pharmaceutical-grade cannabinoid products. More recently, the company is operating in the U.S. as Mandara Biopharma, focused on central nervous system disorders including Alzheimer's disease agitation, post-traumatic stress disorder, and traumatic brain injury. In January 2026, Mandara Biopharma announced an IND filing for a dronabinol oral solution program for agitation associated with Alzheimer's disease, and in February 2026 it announced FDA clearance to initiate clinical trials. The business therefore combines a cannabinoid supply and platform capability with an emerging clinical-stage CNS therapeutics strategy.